OPTIMIZE-2: 4 vs 12 weeks of zoledronic acid for breast cancer bone metastases

Speaker: Robert E. Coleman

R.Coleman explains how the trial results can help plan treatment for women with metastatic breast cancer, highlighting advantages of a less intensified approach. The study was requested by regulatory bodies, originally with placebo in the comparator arm. Due to failed recruitment, the study design was changed. Further trials on bisphosphonates duration are no longer needed.

Discussion Points

The trial focused on the frequency of zoledronic acid for bone metastasis from breast cancer. In this video, Robert E. Coleman discusses:

  • What was the rationale behind the OPTIMIZE-2 trial?
  • What type of improvement was expected with respect to the current practice in this patient population?
  • Short summary of (topline) findings  - How are these findings relevant in comparison to other available treatments (e.g. denosumab) in this setting?